igf 1 lr3 intramuscular 1mg igf 1 lr3 intramuscular IGF-1

Tumor Response Rates Among the 80 patients whose clinical response could be evaluated: 73% of those in the CDDP + GSH group experienced partial or complete remission

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module

Medically reviewed by Alan Lucks | MD , Alan Lucks MDPC Private Practice - New York on January 1st, 2026

This product is intended exclusively for administration by licensed healthcare or aesthetic professionals, as required by applicable local laws and professional guidelines

Exclusion criteria: (1) Patients with abnormal coagulation function [limits: prothrombin time (PT) between 1014 seconds, activated partial thromboplastin time (APTT) between 2540 seconds, and fibrinogen (Fib) levels between 2.04.0 g/L] and immunodeficiency [either primary immunodeficiency (congenital or hereditary conditions leading to impaired immune responses) or secondary immunodeficiency (conditions acquired through HIV infection, chronic immunosuppressive therapy, or severe malnutrition)]